EPS files are the preferred file format for print, because they are vector-based files they are scalable and generally provide the best reproduction. They should be used on all professionally printed pieces.

PNG files are most often used in digital media, such as web and PowerPoint. They have transparent backgrounds, so they are a good choice for non-white backgrounds.

SVG (Scalable Vector Graphics) is a web friendly vector file format.

Download Logo Files

Substitute fonts may be used when working on documents that are being shared internally or externally in their raw format.

This will ensure specialist fonts (as above) will not drop out of the document if they’re not correctly installed on the recipient’s machine.

Below is the preferred brand colour pairing for best legibility and accessibility, across all applications and for large bodies of text.

Colour combinations for supporting elements for graphical objects and pops of large text. Avoid using for large bodies of regular text.

The 60-30-10 colour proportion is a strategic guide intended to maintain visual balance and harmony across all brand assets. It should be used to inform design intuition and decision-making, ensuring that the Dominant colours provide the necessary grounding, the Secondary colours add texture, and the Accent colours retain maximum impact. This is not an exact measure to be precisely calculated on every page or asset, but rather a flexible framework to ensure the brand’s palette is deployed consistently and effectively.

Dominant (60%)

Navy

These foundational, darker, and neutral colours create the bulk of the brand’s sophisticated background and structure.

Secondary (30%)

Green, Blue

Mid-tone colours used for supporting elements, large text blocks, headers, and visual separation.

Accent (10%)

Magenta, Teal

Providing high-contrast emphasis, highlighting key information, calls to action, and the handwritten “extraordinary” element.

When using the MDGH brand, it is important to use the brand colours as shown to establish brand recognition and maintain accessibility.

Photography Style

1. Purpose & Overall Tone

Photography should communicate the dignity, strength, and hope at the heart of our work. Images must feel positive, people-centred, and grounded in real moments. The priority is to show individuals and communities as capable, engaged, and central to their own health journeys, never as passive recipients of aid. The tone should be warm, honest, and human, never staged, sensationalised, or overly polished.

2. Dignity, Ethics & Consent

• Every person photographed must give informed consent, with a parent or guardian consenting for children. Subjects should understand how and where images will be used.
• Portray people as they would wish to be seen: composed, confident, and in control of their own story.
• Never publish images that identify individuals alongside sensitive health information (diagnosis, treatment status) without explicit consent.
• Avoid imagery that exploits vulnerability: visible suffering, distress, or medical procedures shown for emotional effect. Hope and agency, not pity, drive connection.
• Represent communities accurately. Do not stage poverty or select backgrounds to exaggerate hardship.

3. Subjects & Composition

• Hero Shots: Use strong single-subject portraits to highlight individuals: patients, health workers, volunteers, community leaders. These should feel candid rather than posed, capturing a moment of warmth, concentration, or quiet pride.
• Care in Action: Show health workers and community members interacting: a medication being handed over, a consultation, a training session. Frame these as partnerships between people, not services delivered to them.
• Community Representation: Show a mix of ages, genders, and roles, with local staff and community health workers prominent. They are the heroes of this work; international staff should never dominate the frame.
• Framing: Shoot at eye level for connection and equality. Never shoot down on subjects. Keep backgrounds clean; use depth of field to separate subjects from busy environments while retaining a sense of place.

4. Mood & Expression

• Encourage genuine expression: laughter between neighbours, focus during a health check, pride in a job done well.
• Avoid images where people appear distressed, ashamed, or posed as victims.
• Look for moments that show resilience, connection, care, and everyday life continuing: work, family, community.
• A warm, direct gaze to camera is powerful when it conveys confidence and welcome rather than need.

5. Environment & Context

• Health Settings: Capture real conditions in clinics, outreach visits, and community health sessions. Show authentic tools of the work: medication, testing kits, record books, in genuine use.
• Daily Life: Balance health imagery with the wider life of the community: farming, markets, home, play. Health is part of a full life, not the whole story.
• Place: Let environments speak honestly. Landscapes, homes, and villages should appear as they are, softly blurred behind subjects where context supports rather than distracts.

6. Lighting & Colour

• Lighting: Favour natural light, especially the warm tones of early morning and late afternoon. Maintain bright, clean exposure with minimal harsh shadows. Indoor and clinical settings should feel open and calm, not dim or sterile.
• Colour: Maintain accurate, well-rendered skin tones as the highest priority. Let the natural vibrancy of clothing, fabrics, and landscapes carry colour; keep the overall grade warm and consistent with the brand palette.
• Consistency: Avoid high-contrast, desaturated, or moody treatments often associated with crisis imagery. Keep editing subtle and uniform across all photography.

7. Authenticity & Activity

• Prioritise real moments over staged scenarios: people doing, not posing.
• Show the mechanics of the work honestly: distribution, screening, education, follow-up visits.
• Capture micro-moments: a health worker explaining a dosage, children watching a demonstration, a shared laugh at the end of a long day.
• Where re-staging is unavoidable (e.g., for privacy or logistics), keep it faithful to how the activity genuinely happens.

8. Technical Requirements

• Shoot in high resolution for flexibility across print, digital, and campaign use.
• Use shallow depth of field selectively to draw attention to key subjects, especially in busy community environments.
• Maintain sharp focus on the main subject’s eyes.
• Avoid distracting elements: branded third-party clothing, identifiable medical records, or clutter, unless contextually relevant and controlled.
• Caption files with location, date, activity, and consent status to support accurate and ethical use downstream.

The following examples show the MDGH brand in application.

Download Template

For R&D and corporate Microsoft Word documents refer to the following guidelines

Download Template

How your organisation expresses itself in order to establish the desired brand position and set itself apart from the competition.

Professional and trustworthy

Clear, confident, and consistent. Our words are considered and measured, reflecting our deep expertise and unwavering commitment to excellence. We aim to build trust through transparency, accuracy, and a calm, solutions-focused tone.

Curious and evolving 

Inquisitive yet grounded, we speak with a sense of wonder and openness. We ask thoughtful questions, invite new ideas, and communicate with clarity as our projects progress. Our tone is forward-looking and optimistic.

Warm and inclusive  

We speak with authenticity and warmth, showcasing and celebrating the various people involved in all aspects of our work.

With every piece of content we publish, we aim to:

Educate about the need 

Create awareness of the breadth and devastating impact of neglected diseases and the need for a not-for-profit pharmaceutical company to take the lead on the work. 

Showcase the role of MDGH 

Position MDGH as a leader in addressing the problem of neglected diseases by developing new medicines through to regulatory approval, manufacturing, supply chain management and distribution.

Inspire a response 

Provide opportunities for potential funding partners and other individuals and organisations to participate through awareness building, funding and advocacy. 

Communicate collective impact 

Share stories of success, statistical milestones, and collaborative achievements that highlight the significant impact made possible through the various projects.

Medicines Development for Global Health (MDGH) is a not-for-profit pharmaceutical company, developing medicines to ease the burden of neglected diseases on disadvantaged communities worldwide.

Vision

Global health equity through accessible, innovative medicines. 

Mission

We develop and provide access to medicines for diseases that impact underserved communities. 

By reducing the burden of these diseases, MDGH aims to improve health, facilitate people returning to productive activities, like school or work, and overall to have a lasting positive impact on the lives of individuals and communities. 

MDGH achieves this by being a sustainable not-for-profit pharmaceutical company, working in partnership with similarly focussed individuals, companies, organisations, academic institutions, funders and global public health agencies.

Values

• Science-driven: We make decisions based on data.
• Equity: We believe in kindness and a more just society through equal access to opportunities and health equity.
• Courage: We dare to question the status quo and explore different paths in the development of medicines.
• Curiosity: We are inquisitive and share a willingness to learn, create and improve, both individually and as a team.
• Rigour: We are uncompromising in our application of the highest regulatory, ethical and professional standards.

The not-for-profit pharmaceutical company.

Developing medicines to ease the burden of diseases on disadvantaged communities worldwide.

Together, we can improve lives, transform communities, and build a fairer, healthier, and more prosperous world.

Join us in making medicines accessible to all!

Over 1 billion people suffer from neglected diseases often overlooked by traditional pharmaceutical models simply because there is no financial incentive to justify the long and costly process of developing a medicine.

Medicines Development for Global Health (MDGH) is a not-for-profit pharmaceutical company, developing medicines to ease the burden of neglected diseases on many of the world’s most disadvantaged people and communities.

Together, we are improving lives, transforming communities, and building a fairer, healthier and more prosperous world.

Join us in our commitment to make medicines accessible to everyone. 

River blindness summary: 

River blindness (also known as onchocerciasis) is caused by the parasitic worm Onchocerca volvulus, which is transmitted from person to person by black flies that breed in fast flowing rivers, primarily in Africa. The millions of larvae (microfilariae) released by the adult parasites invade skin and eyes where they can cause severe manifestations, including permanent blindness, itching and disfiguring skin conditions.

Despite significant progress, existing treatment strategies for river blindness have been inadequate to achieve disease elimination. The challenge remains vast: nearly 250 million people continue to require preventive chemotherapy for river blindness.

Moxidectin is superior to ivermectin in the treatment of river blindness and has a similar safety profile. (1) With its more profound suppression of microfilariae in more patients and for longer periods than current treatments, moxidectin has the potential to improve lives, interrupt disease transmission, and accelerate the elimination of river blindness, with reduced in-country costs due to requiring less frequent and fewer rounds of treatment overall compared to ivermectin. (2)

In 2025, the Ghana Health Service, Bruyere Institute and University of Health and Allied Sciences in Ghana, in partnership with MDGH, launched the Momentum Project, the first-ever community-based Mass Drug Administration (MDA) of moxidectin in Ghana. The roll-out of moxidectin in Ghana marks the culmination of more than 25 years of work in developing moxidectin for the treatment of river blindness, initiated by the UNICEF/ UNDP/ World Bank/ WHO Special Programme for Research and Training in Tropical Disease (TDR) and Wyeth Pharmaceuticals in the 1990s.

Other community-based MDA pilots are underway in Angola and Cameroon.

1. Opoku. et al. (2018). Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the DRC: a randomised, controlled, double-blind phase 3 trial. The Lancet, 392(10154), 1207–12162
2. Kura. et al. (2023). Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa? Philos Trans R Soc Lond B Biol Sci. 2023; 378(1887): 20220277

Lymphatic filariasis summary:

Lymphatic filariasis (elephantiasis) is caused by parasitic worms spread by infected mosquitoes. This painful and debilitating disease affects the lymph system, leading to severe swelling, chronic pain and long-term disability, often accompanied by social stigma and financial hardship.

MDGH is evaluating the potential of moxidectin-based regimens for the treatment of lymphatic filariasis. New regimens are particularly important for communities in much of Africa where “gold standard” diethylcarbamazine combinations cannot be used due to safety concerns. An alternative treatment with comparable efficacy but without the safety risks is greatly needed to ensure no community is left behind.

Scabies summary:

Scabies is one of the most common contagious skin conditions, affecting people of all ages and backgrounds, worldwide, with more than 200 million people infected at any given time.

Far from a benign skin condition, scabies can cause a cascade of serious health complications that include bacterial infections, kidney disease and rheumatic heart disease. These complications contribute to substantial but under-recognised morbidity and mortality, and pressure on already over-burdened healthcare systems. The burden of scabies infection extends to a person’s whole life, impacting sleep and mental health which leads to time away from work and school. Affected individuals and communities often face stigmatisation, and it presents financial burden with the cost of accessing treatments. For marginalised populations scabies perpetuates the cycle of poverty and disadvantage.

MDGH, in partnership with Atticus Medical, is advancing the development of moxidectin as a potential single-dose oral treatment option that would simplify the treatment of scabies and improve patients’ quality of life.

Existing treatments for scabies are cumbersome to apply, inefficient and are poorly suited to treat entire families or communities. With a high prevalence in under-resourced settings, the disease places a heavy burden on individuals, households, and health systems, hampering well-being.

Leprosy type 2 reaction summary:

Leprosy type 2 reaction is a debilitating and disfiguring immune-mediated inflammatory reaction that can occur as a consequence of a leprosy infection. Consequences can be long lasting and severe, in the worst cases leading to permanent nerve damage, deformities and limb amputation, even death.

Current treatments for leprosy type 2 reaction, including steroid therapy and thalidomide, are prolonged and can cause significant side effects that are often worse than the disease itself. These treatments are not suitable for children or pregnant women.

MDGH is developing a new and improved treatment option to address the unmet need in the care of patients with this horrible disease.

Download Video

Download Video

Download Video

Download Video